Polymyositis

Question 1

Patients with polymyositis experience proximal (asymmetric/symmetric)———-muscle weakness.

Answer 1

Patients with polymyositis experience proximal (asymmetric/symmetric) symmetric muscle weakness.

Question 2

Polymyositis is an inflammatory myopathy that (does/does not)——— involve the skin.

Answer 2

Polymyositis is an inflammatory myopathy that (does/does not) does not involve the skin.

Question 3

The three autoantibodies ——– , anti-SRP, and anti-Mi-2, are associated with polymyositis.

Answer 3

The three autoantibodies anti-Jo-1, anti-SRP, and anti-Mi-2, are associated with polymyositis.

Question 4

Polymyositis is an inflammatory muscle disorder characterized by endomysial inflammation with (CD4/CD8) ——- T cells.

Answer 4

Polymyositis is an inflammatory muscle disorder characterized by endomysial inflammation with (CD4/CD8) CD8 T cells.

Question 5

Vascular injury (does/does not) ——– have a major role in the pathogenesis of polymyositis.

Answer 5

Vascular injury (does/does not) does not have a major role in the pathogenesis of polymyositis.

Question 6

——-is the medication used for long-term immunosuppressive therapy in polymyositis.

Answer 6

Methotrexate is the medication used for long-term immunosuppressive therapy in polymyositis.

Question 7

Skeletal muscle biopsy in a patient with polymyositis usually reveals (endomysial/perimysial) ————-inflammation with necrotic muscle fibers.

Answer 7

Skeletal muscle biopsy in a patient with polymyositis usually reveals (endomysial/perimysial) endomysial inflammation with necrotic muscle fibers.

Question 8

The ——-are the parts of the body most commonly affected by polymyositis.

Answer 8

The shoulders and hips are the parts of the body most commonly affected by polymyositis.

Question 9

Initial treatment of polymyositis is typically ——.

Answer 9

Initial treatment of polymyositis is typically steroids.